Cicero Diagnostics, Inc.  

The ReceptivaDx Test is used by over 425 fertility centers across the US to better understand the reasons for IVF failure, recurrent pregnancy loss and unexplained infertility. The endometrial biopsy test detects the presence of uterine lining inflammation, a condition known to block implantation or cause first trimester pregnancy loss. If detected, the condition can be treated with great success either thru surgery or hormone suppression therapy.... More Info Less Info

The MyReceptiva Test is a powerful new tool that can assist Ob-Gyn and other healthcare providers detect endometriosis with over 90% accuracy. The test is useful for patients with undiagnosed abdominal or pelvic pain, allowing providers the ability to identify women that would benefit most from treatment such as minimally invasive laparoscopy. In addition to patients with pain and suspected endometriosis, the test is also used to assess women with unexplained infertility and recurrent pregnancy loss.
Based on an endometrial biopsy, samples are analyzed for specific inflammatory proteins highly associated with endometriosis. With 93% sensitivity and 96% specificity, the test detects endometriosis with the highest degree of confidence (confirmed via laparoscopy). Test results also include histological dating and a full path analysis.
The MyReceptiva Test has over 20 published clinical papers confirming its clinical utility. The test is endorsed by nationally recognized gynecological surgeons as a powerful assessment tool for endometriosis and is currently used in over 425 US based fertility centers to assess patients experiencing implantation failure and/or pregnancy loss. 
Cicero Diagnostics (based in Henderson, NV) first launched the ReceptivaDx test to the fertility sector of healthcare back in January of 2017. Cicero Diagnostics has since performed over 30,000 analyses to assist the Reproductive Endocrinology community with their most challenging patients by identifying silent or asymptomatic endometriosis, one of the leading causes for IVF failure and pregnancy loss.
Under the brand name, MyReceptiva, a new version of the test is now available to the rest of the womens healthcare community to create broader access to testing. The ability to detect endometriosis in patients with pain, prior family history or women with no symptoms of endo but facing fertility challenges is a major breakthrough in endometriosis testing.... More Info Less Info

MyReceptiva identifies inflammation on the uterine lining  using a protein marker, BCL6, that if present, is highly associated with endometriosis. MyReceptiva was created to help women determine if endometriosis is the cause of their pelvic pain or the reason for their infertility or recurrent pregnancy loss. Offered  through IVF centers for the last 7 years, this test is now available directly to women accessing their Ob-Gyn or Women’s Healthcare provider.... More Info Less Info